Viewing Study NCT07392658


Ignite Creation Date: 2026-03-26 @ 3:18 PM
Ignite Modification Date: 2026-03-31 @ 7:41 AM
Study NCT ID: NCT07392658
Status: RECRUITING
Last Update Posted: 2026-02-06
First Post: 2025-11-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
Sponsor:
Organization:

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Phases:

Phases

Phase Brief Phase Text View
None PHASE2 View
Observational Models:
Time Perspective List:
Who Masked List: